Summary
79.85 3.30(4.31%)09/27/2024
Haemonetics Corp. (HAE)
Haemonetics Corp. (HAE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 4.31 | 6.74 | 4.12 | -4.07 | -5.04 | -9.12 | -35.70 | 1,244.84 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 79.85 | |
| Open | 77.17 | |
| High | 80.62 | |
| Low | 77.14 | |
| Volume | 800,080 | |
| Change | 3.30 | |
| Change % | 4.31 | |
| Avg Volume (20 Days) | 542,479 | |
| Volume/Avg Volume (20 Days) Ratio | 1.47 | |
| 52 Week Range | 70.74 - 97.97 | |
| Price vs 52 Week High | -18.50% | |
| Price vs 52 Week Low | 12.88% | |
| Range | 3.47 | |
| Gap Up/Down | 0.58 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,918 | |
| EBIDTA | 291,246,016 | |
| PE Ratio | 38.9675 | |
| PEG Ratio | 1.6326 | |
| WallStreet Target Price | 105.57 | |
| Book Value | 18.9020 | |
| Earnings Per Share | 2.4600 | |
| EPS Estimate Current Quarter | 0.8900 | |
| EPS Estimate Next Quarter | 1.0300 | |
| EPS Estimate Current Year | 3.9600 | |
| EPS Estimate Next Year | 4.4000 | |
| Diluted EPS (TTM) | 2.4600 | |
| Revenues | ||
| Profit Marging | 0.0898 | |
| Operating Marging (TTM) | 0.1093 | |
| Return on asset (TTM) | 0.0587 | |
| Return on equity (TTM) | 0.1322 | |
| Revenue TTM | 1,309,054,976 | |
| Revenue per share TTM | 25.8170 | |
| Quarterly Revenue Growth (YOY) | 0.1280 | |
| Quarterly Earnings Growth (YOY) | -0.2980 | |
| Gross Profit (TTM) | 530,770,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 38.9675 | |
| Forward PE | 19.6078 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.5880 | |
| Revenue Enterprise Value | 3.9401 | |
| EBITDA Enterprise Value | 18.9838 | |
| Shares | ||
| Shares Outstanding | 50,786,100 | |
| Shares Float | 50,376,133 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.08 | |
| Insider (%) | 0.76 | |
| Institutions (%) | 101.33 | |
09/27 12:46 EST - zacks.com
HAE vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
HAE vs. BSX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
09/26 09:51 EST - zacks.com
Here's Why You Should Add HAE Stock in Your Portfolio Now
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
Here's Why You Should Add HAE Stock in Your Portfolio Now
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
09/24 09:11 EST - zacks.com
4 Medical Product Stocks to Buy From a Prospective Industry
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
4 Medical Product Stocks to Buy From a Prospective Industry
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
09/12 07:30 EST - globenewswire.com
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that data from the Phase 2 study of NTLA-2002 will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24 – 28 in Boston, Massachusetts. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema (HAE), a rare genetic condition that leads to potentially life-threatening swelling attacks.
09/11 12:41 EST - zacks.com
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
09/05 06:49 EST - globenewswire.com
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, is highlighting the differentiated profile of deucrictibant as a prophylactic and on-demand treatment of HAE attacks at the Bradykinin Symposium 2024, being held in Berlin from September 5-6, 2024. A summary of the data being presented at the congress can be found here.
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, is highlighting the differentiated profile of deucrictibant as a prophylactic and on-demand treatment of HAE attacks at the Bradykinin Symposium 2024, being held in Berlin from September 5-6, 2024. A summary of the data being presented at the congress can be found here.
09/02 10:36 EST - zacks.com
After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)
Haemonetics (HAE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)
Haemonetics (HAE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
08/16 10:10 EST - zacks.com
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
Haemonetics (HAE) Set to Launch VASCADE MVP XL in US
Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.
08/16 07:57 EST - benzinga.com
Top 3 Health Care Stocks That Are Set To Fly This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks That Are Set To Fly This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
08/15 06:30 EST - prnewswire.com
Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System
BOSTON , Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.
Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System
BOSTON , Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.
08/12 08:50 EST - zacks.com
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises
Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.
08/09 10:46 EST - zacks.com
Is Haemonetics (HAE) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Haemonetics (HAE) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
08/09 10:36 EST - zacks.com
Down -14.6% in 4 Weeks, Here's Why Haemonetics (HAE) Looks Ripe for a Turnaround
Haemonetics (HAE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -14.6% in 4 Weeks, Here's Why Haemonetics (HAE) Looks Ripe for a Turnaround
Haemonetics (HAE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
08/08 13:13 EST - seekingalpha.com
Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Olga Guyette – Vice President, Investor Relations and Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Americas Mike Matson – Needham Andrew Cooper – Raymond James Larry Solow – CJS Securities Joanne Wuensch – Citi Michael Petusky – Barrington Research Operator Thank you for standing by, and welcome to Haemonetics Corporation's First Quarter Fiscal Year 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Olga Guyette – Vice President, Investor Relations and Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Americas Mike Matson – Needham Andrew Cooper – Raymond James Larry Solow – CJS Securities Joanne Wuensch – Citi Michael Petusky – Barrington Research Operator Thank you for standing by, and welcome to Haemonetics Corporation's First Quarter Fiscal Year 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
08/08 08:25 EST - zacks.com
Haemonetics (HAE) Misses Q1 Earnings Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.05 per share a year ago.
Haemonetics (HAE) Misses Q1 Earnings Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.05 per share a year ago.
08/08 06:00 EST - prnewswire.com
Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
08/07 10:55 EST - zacks.com
Wall Street Analysts See a 30.13% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 30.13% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
08/07 10:40 EST - zacks.com
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.